Malignant cardiac phenotypic expression of Danon disease (LAMP2 cardiomyopathy)
Recommended Citation
Samad F, Jain R, Jan MF, et al. Malignant cardiac phenotypic expression of Danon disease (LAMP2 cardiomyopathy). Int J Cardiol. 2017;245:201-206. doi: 10.1016/j.ijcard.2017.06.031.
Abstract
INTRODUCTION: Danon disease is an X-linked lysosomal condition that causes a deficiency of lysosome-associated membrane protein 2 (LAMP2) gene. It is characterized clinically by a triad of skeletal myopathy, cardiomyopathy, and intellectual disability.
METHODS: We examined clinical, echocardiographic, and genetic data on 5 patients with Danon disease, highlighting their clinical course and outcomes.
RESULTS: All patients presented phenotypically with hypertrophic cardiomyopathy and later developed systolic dysfunction. The mean age at diagnosis was 19years (11-31years). All patients had diastolic dysfunction (mean e' of 5cm/s [3.5-6cm/s], mean E/e' of 17 [15-21]). Three patients required cardiac transplantation (ages 15, 27, and 42). Of the two deaths in this group, both were in women.
CONCLUSION: We highlight the aggressive cardiac phenotype of Danon disease in our clinical experience with rapid progression to end-stage cardiomyopathy; this progression occurred in both men and women. A timely diagnosis and an early referral for cardiac transplantation is crucial for improved outcomes.
Document Type
Article
PubMed ID
28874292
Affiliations
Aurora Cardiovascular Services, Department of Internal Medicine, Aurora Sinai/Aurora St. Luke's Medical Centers, Center for Integrative Research on Cardiovascular Aging (CIRCA), Aurora Research Institute